tocilizumab SSc-ILD
Selected indexed studies
- Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. (Lancet Respir Med, 2020) [PMID:32866440]
- Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database. (Ann Rheum Dis, 2025) [PMID:39894689]
- Current advances in the treatment of systemic sclerosis. (Curr Opin Pharmacol, 2022) [PMID:35447517]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025. (2025) pubmed
- Tocilizumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. (2024) pubmed
- Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. (2020) pubmed
- Current advances in the treatment of systemic sclerosis. (2022) pubmed
- Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. (2024) pubmed
- Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. (2023) pubmed
- Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results. (2024) pubmed
- Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database. (2025) pubmed
- Macrophages as determinants and regulators of systemic sclerosis-related interstitial lung disease. (2024) pubmed
- Nerandomilast Improves Bleomycin-Induced Systemic Sclerosis-Associated Interstitial Lung Disease in Mice by Regulating the TGF-β1 Pathway. (2025) pubmed